<!DOCTYPE html><html><head><style>
      /* Create a running element */
      #header-and-footer {
        position: running(header-and-footer);
        text-align: right;
      }

      /* Add that running element to the top and bottom of every page */
      @page {
        @top {
          content: element(header-and-footer);
        }
        @bottom {
          content: element(header-and-footer);
        }
      }

      /* Add a page number */
      #page-number {
        content: "Page " counter(page);
      }

      /* Create a title page with a full-bleed background and no header */
      #title-page {
        page: title-page;
      }

      @page title-page {
        @top {
          content: "";
        }
      }

      #title-page h1 {
        padding: 200px 0 40px 0;
        font-size: 30px;
      }

      /* Dynamically create a table of contents with leaders */
      #table-of-contents a {
        content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
        color: #000000;
        text-decoration: none;
        display: block;
        padding-top: 5px;
      }

      /* Float the footnote to a footnotes area on the page */
      .footnote {
        float: footnote;
        font-size: small;
      }

      .page {
        page-break-after: always;
      }

      body {
        counter-reset: chapter;
        font-family: 'Times New Roman';
        color: #000000;
      }
    </style>
    <link href='https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&display=swap' rel='stylesheet'>
    </style></head><body>
      <div id="title-page" class="page">
        <h1>Simple Test 1</h1>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
      <div id="toc-page" class="page">
        <div id="table-of-contents">
          <a href="#section-0"></a><a href="#section-1"></a><a href="#section-2"></a><a href="#section-3"></a><a href="#section-4"></a><a href="#section-5"></a><a href="#section-6"></a><a href="#section-7"></a><a href="#section-8"></a><a href="#section-9"></a><a href="#section-10"></a><a href="#section-11"></a><a href="#section-12"></a><a href="#section-13"></a><a href="#section-14"></a><a href="#section-15"></a>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    <div class="page"><h1 id="section-0">0&nbspTITLE PAGE</h1><table><tr><th style="vertical-align: top; text-align: left"><p>Protocol Full Title:</p></th><td style="vertical-align: top; text-align: left"><p>Something Very Official</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Protocol Number:</p></th><td style="vertical-align: top; text-align: left"><p>AP1234</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version:&gt;</p></th><td style="vertical-align: top; text-align: left"><p>1</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Number:</p></th><td style="vertical-align: top; text-align: left"><p>4</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Scope:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Number(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Name(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Phase:</p></th><td style="vertical-align: top; text-align: left"><p>Phase III Trial</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Acronym:</p></th><td style="vertical-align: top; text-align: left"><p>SIMPLE</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Short Title:</p></th><td style="vertical-align: top; text-align: left"><p>Something Brief</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Name and Address:</p></th><td style="vertical-align: top; text-align: left"><p>ACME Pharma<br/>Somewhere, In a City, In a District, In a big state, 12345, France</p></td></tr></table></div><div class="page"><h1 id="section-1">1&nbspPROTOCOL SUMMARY</h1><div></div><div class=""><h2 id="section-1.1">1.1&nbspProtocol Synopsis</h2><div></div></div><div class=""><h2 id="section-1.2">1.2&nbspTrial Schema</h2><div></div></div><div class=""><h2 id="section-1.3">1.3&nbspSchedule of Activities</h2><div></div></div></div><div class="page"><h1 id="section-2">2&nbspINTRODUCTION</h1><div></div><div class=""><h2 id="section-2.1">2.1&nbspPurpose of Trial</h2><div></div></div><div class=""><h2 id="section-2.2">2.2&nbspSummary of Benefits and Risks</h2><div></div></div></div><div class="page"><h1 id="section-3">3&nbspTRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS</h1><div></div><div class=""><h2 id="section-3.1">3.1&nbspPrimary Objectives</h2><div><table>
<tr>
<th style="vertical-align: top">Primary Objective</th>
<th style="vertical-align: top">Primary Endpoint</th>
</tr>
<tr>
<td style="vertical-align: top">Primary</td>
<td style="vertical-align: top">Day 28, 7 category scale</td>
</tr>
</table></div></div></div><div class="page"><h1 id="section-4">4&nbspTRIAL DESIGN</h1><div></div><div class=""><h2 id="section-4.1">4.1&nbspDescription of Trial Design</h2><div></div><div class=""><h3 id="section-4.1.1">4.1.1&nbspParticipant Input into Design</h3><div></div></div></div><div class=""><h2 id="section-4.2">4.2&nbspRationale for Trial Design</h2><div></div><div class=""><h3 id="section-4.2.1">4.2.1&nbspRationale for Comparator</h3><div></div></div><div class=""><h3 id="section-4.2.2">4.2.2&nbspRationale for Adaptive or Novel Trial Design</h3><div></div></div><div class=""><h3 id="section-4.2.3">4.2.3&nbspOther Trial Design Considerations</h3><div></div></div></div><div class=""><h2 id="section-4.3">4.3&nbspAccess to Trial Intervention After End of Trial</h2><div></div></div><div class=""><h2 id="section-4.4">4.4&nbspStart of Trial and End of Trial</h2><div></div></div></div><div class="page"><h1 id="section-5">5&nbspTRIAL POPULATION</h1><div></div><div class=""><h2 id="section-5.1">5.1&nbspSelection of Trial Population</h2><div></div></div><div class=""><h2 id="section-5.2">5.2&nbspRationale for Trial Population</h2><div></div></div><div class=""><h2 id="section-5.3">5.3&nbspInclusion Criteria</h2><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p><table><tr><td style="vertical-align: top; text-align: left"><p>1</p></td><td style="vertical-align: top; text-align: left"><p>Subjects shall be between [min_age] and [max_age]</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>2</p></td><td style="vertical-align: top; text-align: left"><p>Subjects shall be between [min_age] and [max_agexxx]</p></td></tr></table></div><div class=""><h2 id="section-5.4">5.4&nbspExclusion Criteria</h2><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p><table></table></div><div class=""><h2 id="section-5.5">5.5&nbspLifestyle Considerations</h2><div></div><div class=""><h3 id="section-5.5.1">5.5.1&nbspMeals and Dietary Restrictions</h3><div></div></div><div class=""><h3 id="section-5.5.2">5.5.2&nbspCaffeine, Alcohol, Tobacco, and Other Habits</h3><div></div></div><div class=""><h3 id="section-5.5.3">5.5.3&nbspPhysical Activity</h3><div></div></div><div class=""><h3 id="section-5.5.4">5.5.4&nbspOther Activity</h3><div></div></div></div><div class=""><h2 id="section-5.6">5.6&nbspScreen Failures</h2><div></div></div></div><div class="page"><h1 id="section-6">6&nbspTRIAL INTERVENTION AND CONCOMITANT THERAPY</h1><div></div><div class=""><h2 id="section-6.1">6.1&nbspDescription of Trial Intervention</h2><div></div></div><div class=""><h2 id="section-6.2">6.2&nbspRationale for Trial Intervention</h2><div></div></div><div class=""><h2 id="section-6.3">6.3&nbspDosing and Administration</h2><div></div><div class=""><h3 id="section-6.3.1">6.3.1&nbspTrial Intervention Dose Modification</h3><div></div></div></div><div class=""><h2 id="section-6.4">6.4&nbspTreatment of Overdose</h2><div></div></div><div class=""><h2 id="section-6.5">6.5&nbspPreparation, Handling, Storage and Accountability</h2><div></div><div class=""><h3 id="section-6.5.1">6.5.1&nbspPreparation of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-6.5.2">6.5.2&nbspHandling and Storage of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-6.5.3">6.5.3&nbspAccountability of Trial Intervention</h3><div></div></div></div><div class=""><h2 id="section-6.6">6.6&nbspParticipant Assignment, Randomisation and Blinding</h2><div></div><div class=""><h3 id="section-6.6.1">6.6.1&nbspParticipant Assignment</h3><div></div></div><div class=""><h3 id="section-6.6.2">6.6.2&nbspRandomisation</h3><div></div></div><div class=""><h3 id="section-6.6.3">6.6.3&nbspBlinding and Unblinding</h3><div><p>Blinding and unblinding text here please</p></div></div></div><div class=""><h2 id="section-6.7">6.7&nbspTrial Intervention Compliance</h2><div></div></div><div class=""><h2 id="section-6.8">6.8&nbspConcomitant Therapy</h2><div></div><div class=""><h3 id="section-6.8.1">6.8.1&nbspProhibited Concomitant Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.2">6.8.2&nbspPermitted Concomitant Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.3">6.8.3&nbspRescue Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.4">6.8.4&nbspOther Therapy</h3><div></div></div></div></div><div class="page"><h1 id="section-7">7&nbspDISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL</h1><div></div><div class=""><h2 id="section-7.1">7.1&nbspDiscontinuation of Trial Intervention</h2><div></div><div class=""><h3 id="section-7.1.1">7.1.1&nbspCriteria for Permanent Discontinuation of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-7.1.2">7.1.2&nbspTemporary Discontinuation or Interruption of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-7.1.3">7.1.3&nbspRechallenge</h3><div></div></div></div><div class=""><h2 id="section-7.2">7.2&nbspParticipant Withdrawal from the Trial</h2><div></div></div><div class=""><h2 id="section-7.3">7.3&nbspLost to Follow-Up</h2><div></div></div><div class=""><h2 id="section-7.4">7.4&nbspTrial Stopping Rules</h2><div></div></div></div><div class="page"><h1 id="section-8">8&nbspTRIAL ASSESSMENTS AND PROCEDURES</h1><div></div><div class=""><h2 id="section-8.1">8.1&nbspScreening/Baseline Assessments and Procedures</h2><div></div></div><div class=""><h2 id="section-8.2">8.2&nbspEfficacy Assessments and Procedures</h2><div></div></div><div class=""><h2 id="section-8.3">8.3&nbspSafety Assessments and Procedures</h2><div></div><div class=""><h3 id="section-8.3.1">8.3.1&nbspPhysical Examination</h3><div></div></div><div class=""><h3 id="section-8.3.2">8.3.2&nbspVital Signs</h3><div></div></div><div class=""><h3 id="section-8.3.3">8.3.3&nbspElectrocardiograms</h3><div></div></div><div class=""><h3 id="section-8.3.4">8.3.4&nbspClinical Laboratory Assessments</h3><div></div></div><div class=""><h3 id="section-8.3.5">8.3.5&nbspSuicidal Ideation and Behaviour Risk Monitoring</h3><div></div></div></div><div class=""><h2 id="section-8.4">8.4&nbspAdverse Events and Serious Adverse Events</h2><div></div><div class=""><h3 id="section-8.4.1">8.4.1&nbspDefinitions of AE and SAE</h3><div></div></div><div class=""><h3 id="section-8.4.2">8.4.2&nbspTime Period and Frequency for Collecting AE and SAE Information</h3><div></div></div><div class=""><h3 id="section-8.4.3">8.4.3&nbspIdentifying AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.4">8.4.4&nbspRecording of AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.5">8.4.5&nbspFollow-up of AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.6">8.4.6&nbspReporting of SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.7">8.4.7&nbspRegulatory Reporting Requirements for SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.8">8.4.8&nbspSerious and Unexpected Adverse Reaction Reporting</h3><div></div></div><div class=""><h3 id="section-8.4.9">8.4.9&nbspAdverse Events of Special Interest</h3><div></div></div><div class=""><h3 id="section-8.4.10">8.4.10&nbspDisease-related Events or Outcomes Not Qualifying as AEs or SAEs</h3><div></div></div></div><div class=""><h2 id="section-8.5">8.5&nbspPregnancy and Postpartum Information</h2><div></div><div class=""><h3 id="section-8.5.1">8.5.1&nbspParticipants Who Become Pregnant During the Trial</h3><div></div></div><div class=""><h3 id="section-8.5.2">8.5.2&nbspParticipants Whose Partners Become Pregnant</h3><div></div></div></div><div class=""><h2 id="section-8.6">8.6&nbspMedical Device Product Complaints for Drug/Device Combination Products</h2><div></div><div class=""><h3 id="section-8.6.1">8.6.1&nbspDefinition of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.2">8.6.2&nbspRecording of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.3">8.6.3&nbspTime Period and Frequency for Collecting Medical Device Product Complaints .</h3><div></div></div><div class=""><h3 id="section-8.6.4">8.6.4&nbspFollow-Up of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.5">8.6.5&nbspRegulatory Reporting Requirements for Medical Device Product Complaints</h3><div></div></div></div><div class=""><h2 id="section-8.7">8.7&nbspPharmacokinetics</h2><div></div></div><div class=""><h2 id="section-8.8">8.8&nbspGenetics</h2><div></div></div><div class=""><h2 id="section-8.9">8.9&nbspBiomarkers</h2><div></div></div><div class=""><h2 id="section-8.1">8.1&nbspImmunogenicity Assessments</h2><div></div><div class=""><h3 id="section-8.1.1">8.1.1&nbspMedical Resource Utilisation and Health Economics</h3><div></div></div></div></div><div class="page"><h1 id="section-9">9&nbspSTATISTICAL CONSIDERATIONS</h1><div></div><div class=""><h2 id="section-9.1">9.1&nbspAnalysis Sets</h2><div></div></div><div class=""><h2 id="section-9.2">9.2&nbspAnalyses Supporting Primary Objective(s)</h2><div></div><div class=""><h3 id="section-9.2.1">9.2.1&nbspStatistical Model, Hypothesis, and Method of Analysis</h3><div></div></div><div class=""><h3 id="section-9.2.2">9.2.2&nbspHandling of Intercurrent Events of Primary Estimand(s)</h3><div></div></div><div class=""><h3 id="section-9.2.3">9.2.3&nbspHandling of Missing Data</h3><div></div></div><div class=""><h3 id="section-9.2.4">9.2.4&nbspSensitivity Analysis</h3><div></div></div><div class=""><h3 id="section-9.2.5">9.2.5&nbspSupplementary Analysis</h3><div></div></div></div><div class=""><h2 id="section-9.3">9.3&nbspAnalysis Supporting Secondary Objective(s)</h2><div></div></div><div class=""><h2 id="section-9.4">9.4&nbspAnalysis of Exploratory Objective(s)</h2><div></div></div><div class=""><h2 id="section-9.5">9.5&nbspSafety Analyses</h2><div></div></div><div class=""><h2 id="section-9.6">9.6&nbspOther Analyses</h2><div></div></div><div class=""><h2 id="section-9.7">9.7&nbspInterim Analyses</h2><div></div></div><div class=""><h2 id="section-9.8">9.8&nbspSample Size Determination</h2><div></div></div><div class=""><h2 id="section-9.9">9.9&nbspProtocol Deviations</h2><div></div></div></div><div class="page"><h1 id="section-10">10&nbspGENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT</h1><div></div><div class=""><h2 id="section-10.1">10.1&nbspRegulatory and Ethical Considerations</h2><div></div></div><div class=""><h2 id="section-10.2">10.2&nbspCommittees</h2><div></div></div><div class=""><h2 id="section-10.3">10.3&nbspInformed Consent Process</h2><div></div></div><div class=""><h2 id="section-10.4">10.4&nbspData Protection</h2><div></div></div><div class=""><h2 id="section-10.5">10.5&nbspEarly Site Closure or Trial Termination</h2><div></div></div></div><div class="page"><h1 id="section-11">11&nbspGENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE</h1><div></div><div class=""><h2 id="section-11.1">11.1&nbspQuality Tolerance Limits</h2><div></div></div><div class=""><h2 id="section-11.2">11.2&nbspData Quality Assurance</h2><div></div></div><div class=""><h2 id="section-11.3">11.3&nbspSource Data</h2><div></div></div></div><div class="page"><h1 id="section-12">12&nbspAPPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY</h1><div></div><div class=""><h2 id="section-12.1">12.1&nbspFurther Details and Clarifications on the AE Definition</h2><div></div></div><div class=""><h2 id="section-12.2">12.2&nbspFurther Details and Clarifications on the SAE Definition</h2><div></div></div><div class=""><h2 id="section-12.3">12.3&nbspSeverity</h2><div></div></div><div class=""><h2 id="section-12.4">12.4&nbspCausality</h2><div></div></div></div><div class="page"><h1 id="section-13">13&nbspAPPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS</h1><div></div><div class=""><h2 id="section-13.1">13.1&nbspContraception and Pregnancy Testing</h2><div></div><div class=""><h3 id="section-13.1.1">13.1.1&nbspDefinitions Related to Childbearing Potential</h3><div></div></div><div class=""><h3 id="section-13.1.2">13.1.2&nbspContraception</h3><div></div></div><div class=""><h3 id="section-13.1.3">13.1.3&nbspPregnancy Testing</h3><div></div></div></div><div class=""><h2 id="section-13.2">13.2&nbspClinical Laboratory Tests</h2><div></div></div><div class=""><h2 id="section-13.3">13.3&nbspCountry/Region-Specific Differences</h2><div></div></div><div class=""><h2 id="section-13.4">13.4&nbspPrior Protocol Amendments</h2><div></div></div></div><div class="page"><h1 id="section-14">14&nbspAPPENDIX: GLOSSARY OF TERMS</h1><div></div></div><div class="page"><h1 id="section-15">15&nbspAPPENDIX: REFERENCES</h1><div></div></div></body></html>